Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 449

1.

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV.

J Urol. 2006 Sep;176(3):972-8; discussion 978.

PMID:
16890673
2.

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.

J Urol. 2003 Jun;169(6):2008-12.

PMID:
12771706
3.

Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.

Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ.

BJU Int. 2007 Jul;100(1):70-5.

4.

Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.

Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.

J Urol. 2009 Nov;182(5):2257-64. doi: 10.1016/j.juro.2009.07.046. Epub 2009 Sep 16.

PMID:
19758618
5.

The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.

Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, Tran DN, Warsi GM, Lacerna LV.

Clin Genitourin Cancer. 2007 Mar;5(4):271-7.

PMID:
17553207
6.

Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.

Polascik TJ, Given RW, Metzger C, Julian SR, Vestal JC, Karlin GS, Barkley CS, Bilhartz DL, McWhorter LT, Lacerna LV.

Urology. 2005 Nov;66(5):1054-9.

PMID:
16286123
7.

Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.

Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S.

Cancer. 2009 Aug 1;115(15):3468-74. doi: 10.1002/cncr.24404.

8.

Long term zoledronic acid during androgen blockade for prostate cancer.

Casey R, Gesztesi Z, Rochford J.

Can J Urol. 2010 Jun;17(3):5170-7.

PMID:
20566009
9.

Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.

Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT.

Urology. 2007 Jul;70(1):122-6.

PMID:
17656221
10.

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.

Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA; Z-FAST and ZO-FAST Study Groups.

Oncologist. 2008 May;13(5):503-14. doi: 10.1634/theoncologist.2007-0206.

13.

Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.

Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K.

Int J Urol. 2007 Dec;14(12):1071-5.

14.

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.

Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.

Prostate Cancer Prostatic Dis. 2002;5(4):304-10.

15.

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS.

N Engl J Med. 2001 Sep 27;345(13):948-55.

16.

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.

Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA.

J Clin Oncol. 2007 Mar 1;25(7):829-36. Epub 2006 Dec 11.

PMID:
17159193
17.

Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.

Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.

J Urol. 2006 May;175(5):1679-83; discussion 1683.

PMID:
16600728
18.

Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.

Doggrell SA.

Expert Rev Anticancer Ther. 2009 Sep;9(9):1211-8. doi: 10.1586/era.09.95. Review.

PMID:
19761424
19.

Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ.

N Engl J Med. 2002 Feb 28;346(9):653-61.

20.

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

Kiratli BJ, Srinivas S, Perkash I, Terris MK.

Urology. 2001 Jan;57(1):127-32.

PMID:
11164157

Supplemental Content

Support Center